Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab

被引：0
|
作者：
Kristeleit, R. [1 ]
Matthews, C. [2 ]
Redondo, A. [3 ]
Huang, J. [4 ]
Eliason, L. [4 ]
Im, E. [4 ]
Brown, J. [5 ]
机构：
[1] NHS Fdn Trust, Guys & St Thomas Hosp, Dept Oncol, London, England
[2] Women & Infants Hosp Rhode Isl, Womens Oncol, Providence, RI 02908 USA
[3] Hosp Univ La Paz IdiPAZ, Med Oncol Dept, Madrid, Spain
[4] GlaxoSmithKline, Clin Sci, Waltham, MA USA
[5] Atrium Hlth, Levine Inst, Gy0ecol Oncol, Charlotte, NC USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.997
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
858P
引用
收藏
页码：S637 / S637
页数：1
相关论文
共 50 条
  • [41] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    [J]. ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [42] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
  • [43] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
    Overman, Michael J.
    Lenz, Heinz-Josef
    Andre, Thierry
    Aglietta, Massimo
    Wong, Mark Ka
    Luppi, Gabriele
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hendlisz, Alain
    Cardin, Dana Backlund
    Morse, Michael
    Neyns, Bart
    Hill, Andrew Graham
    Limon, M. Luisa
    Garcia-Alfonso, Pilar
    Krishnamurthy, Anuradha
    Chen, Franklin
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lonardi, Sara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Evaluating the patient-level association between progression-free survival and overall survival in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (MSI-H/dMMR mCRC) treated with immune checkpoint inhibitors
    Roodhart, J. M. L.
    Sharpe, D. J.
    Tate, A. E.
    Bertwistle, D.
    Dixon, M.
    Chen, H-H.
    Kurt, M.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S27 - S27
  • [45] Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
    Feng Bi
    Jian Dong
    Chuan Jin
    Zuoxing Niu
    Wenhui Yang
    Yifu He
    Dajun Yu
    Meili Sun
    Teng Wang
    Xianli Yin
    Ruixing Zhang
    Kehe Chen
    Keming Wang
    Zhiwu Wang
    Wei Li
    Zhongtao Zhang
    Hangyu Zhang
    Qunyi Guo
    Xin Wang
    Lei Han
    Xizhi Zhang
    Wei Shen
    Liangming Zhang
    Jieer Ying
    Miao Wu
    Weiguo Hu
    Zeng Li
    Xiaofen Li
    Wenlei Feng
    Baihui Zhang
    Lingyan Li
    Xiaoyan Kang
    Weijian Guo
    [J]. Journal of Hematology & Oncology, 17 (1)
  • [46] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
    Lonardi, S.
    Andre, T.
    Wong, K. Y. M.
    Morse, M.
    McDermott, R.
    Hill, A.
    Hendlisz, A.
    Lenz, H.
    Leach, J.
    Moss, R. A.
    Cao, Z. A.
    Ledeine, J.
    Kopetz, S.
    Overman, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
  • [48] Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial
    Mirza, Mansoor Raza
    Powell, Matthew A.
    Lundgren, Caroline
    Sukhin, Vladyslav
    Pothuri, Bhavana
    Gilbert, Lucy
    Gill, Sarah
    Ronzino, Graziana
    Nevadunsky, Nicole
    Kommoss, Stefan
    Willmott, Lyndsay
    Boere, Ingrid
    Mathews, Cara Amanda
    Buscema, Joseph
    Teneriello, Michael
    Shahin, Mark S.
    Meyers, Oren
    Garside, Jamie
    Coleman, Robert L.
    Slomovitz, Brian M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Literature review and meta-analyses of the prevalence of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) for colorectal (CRC), gastric (GC), endometrial (EC) and ovarian cancers (OC) in Chinese population
    Liu, Xiaoqiao
    Fan, Jiaqi
    Liaw, Kai-Li
    Xu, Mo
    Zhou, Yu
    Amonkar, Mayur
    Zeng, Gefei
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [50] Patient-reported outcomes in DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer treated with nivolumab: CheckMate 142
    Michael, Overman
    Shital, Kamble
    Rebecca, Moss
    Fiona, Taylor
    Gregory, Maglinte
    James, Shaw
    Kim, Cocks
    Erin, Mann
    Christine, Yip
    Thierry, Andre
    [J]. ANNALS OF ONCOLOGY, 2017, 28
12345